<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40986451</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8593</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Diabetes technology &amp; therapeutics</Title><ISOAbbreviation>Diabetes Technol Ther</ISOAbbreviation></Journal><ArticleTitle>Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1177/15209156251380860</ELocationID><Abstract><AbstractText><b><i>Objective:</i></b> To assess feasibility and safety of a decision support system (AI-DSS) that provides algorithm-generated insulin dosing recommendations directly to individuals with type 1 diabetes (T1D) managed with multiple daily injections (MDI). <b><i>Methods:</i></b> This single-arm, prospective proof-of-concept study included individuals with T1D managed with MDI and continuous glucose monitoring (CGM). Participants underwent a 4-week run-in period followed by a 12-week intervention phase, during which every two weeks&#xa0;algorithm-generated insulin titration recommendations were provided via a mobile application. CGM metrics were compared between the last 2 weeks of the run-in (baseline) and the last 2 weeks of the intervention periods. Primary safety outcomes included percent time &lt;54 mg/dL and &gt;250 mg/dL. Secondary outcomes included changes in HbA1c and time in range (TIR, 70-180 mg/dL). <b><i>Results:</i></b> The study cohort included 16 young adults (mean age 25.1 &#xb1; 4.1 years; 56% female, mean HbA1c 7.6% &#xb1; 0.8%) who completed the study. Median HbA1c significantly decreased from 7.5% (IQR: 7.1, 8) to 7.1% (IQR: 6.5, 7.3), from start to end of study (<i>P</i> = 0.013). TIR significantly improved by 3.5% &#xb1; 7.3% (<i>P</i> = 0.039). Time &lt;54 mg/dL remained unchanged (0.9% &#xb1; 0.86% vs. 1.12% &#xb1; 1.11%; <i>P</i> = 0.191), with a trend toward reduced time &gt;250 mg/dL (14.3% &#xb1; 10.71% vs. 12.32% &#xb1; 10.91%; <i>P</i> = 0.055). No severe adverse events were reported. <b><i>Conclusion:</i></b> Decision support tool for self-managed insulin dosing in individuals with T1D using MDI was feasible, safe, and improved glycemic control, supporting further evaluation in large-scale randomized trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nimri</LastName><ForeName>Revital</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3571-4938</Identifier><AffiliationInfo><Affiliation>Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weizman Demri</LastName><ForeName>Sarit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisch-Shvalb</LastName><ForeName>Naama</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9612-6983</Identifier><AffiliationInfo><Affiliation>Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>DreaMed Diabetes, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raz</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DreaMed Diabetes, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atlas</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>DreaMed Diabetes, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillip</LastName><ForeName>Moshe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Technol Ther</MedlineTA><NlmUniqueID>100889084</NlmUniqueID><ISSNLinking>1520-9156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">decision support system</Keyword><Keyword MajorTopicYN="N">insulin titration</Keyword><Keyword MajorTopicYN="N">multiple daily injections</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>13</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40986451</ArticleId><ArticleId IdType="doi">10.1177/15209156251380860</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>